Immunotech Laboratories, Inc. is a drug development company. The company is headquartered in Glendale, California and currently employs 4 full-time employees. The company went IPO on 2002-01-07. The firm is also focused on the commercialization of its proprietary proteins known as Irreversible Pepsin Fraction (IPF) ITV-1 for the treatment of debilitating infectious diseases, such as human immunodeficiency virus (HIV) and Hepatitis Type C.
